IRMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IRadimed Corp (IRMD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst ratings, and unique product offerings in a niche market support a bullish stance. Despite some short-term technical weakness, the long-term growth potential and international expansion opportunities make it a solid investment.
The MACD is negatively expanding with a histogram of -0.45, indicating bearish momentum. RSI is at 27.597, which is neutral but leaning towards oversold territory. Moving averages are converging, showing no clear trend. The stock is trading near its S1 support level of 89.273, with further support at 87.013. Resistance levels are at 92.933 and 96.593.
Strong financial performance in Q4 2025, with revenue up 17.03% YoY, net income up 25.16% YoY, and EPS up 25.00% YoY.
Positive analyst ratings with price targets raised to $116-$120, citing product-driven upgrade cycles, international expansion, and strong execution.
Unique product offerings in a niche market, including MRI-compatible devices.
Gross margin dropped slightly by -1.41% YoY in Q4
Technical indicators show short-term bearish momentum with MACD and converging moving averages.
No significant hedge fund or insider trading activity, indicating neutral sentiment.
In Q4 2025, IRadimed reported strong growth: Revenue increased by 17.03% YoY to $22.69M, Net Income rose by 25.16% YoY to $6.44M, and EPS grew by 25.00% YoY to $0.50. However, gross margin slightly declined to 75.06%, down -1.41% YoY.
Analysts maintain a bullish stance on IRMD, with multiple Buy ratings and price targets raised to $116-$120. Analysts highlight the company's strong execution, profitability, and growth potential driven by product upgrades, international expansion, and the launch of new products like the 3870 pump.
